

## Apixaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to <b>dabigatran</b> for <input type="text" value="Venous thromboembolism"/> Therapeutic equivalent to <b>dabigatran</b> for <input type="text" value="Other specified atrial fibrillation"/>

## Dabigatran

Section	Indications
Medicines affecting coagulation Oral > Solid: 110 mg; 150 mg	<input type="text" value="Venous thromboembolism"/> <input type="text" value="Other specified atrial fibrillation"/>

## Dalteparin

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to <b>enoxaparin</b> for <input type="text" value="Acute ischaemic heart disease"/> Therapeutic equivalent to <b>enoxaparin</b> for <input type="text" value="Venous thromboembolism"/>

## Desmopressin

Section	Indications
Medicines affecting coagulation Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate) Local > Nasal > Spray: 10 µg per dose (acetate)	<input type="text" value="Haemophilia A"/> <input type="text" value="Von Willebrand disease"/>

## Edoxaban

Section	Indications
Medicines affecting coagulation	Therapeutic equivalent to <b>dabigatran</b> for <input type="text" value="Venous thromboembolism"/> Therapeutic equivalent to <b>dabigatran</b> for <input type="text" value="Other specified atrial fibrillation"/>

## Enoxaparin

### Section

#### Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

### Indications

Acute ischaemic heart disease

Venous thromboembolism

## Heparin sodium

### Section

#### Medicines affecting coagulation

Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule; 20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule

### Indications

Venous thromboembolism

Unstable angina

Acute ischaemic heart disease

## Nadroparin

### Section

#### Medicines affecting coagulation

### Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

## Phytomenadione

### Section

#### Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule  
Oral > Solid: 10 mg tablet

### Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

Haemorrhagic or haematological disorders of fetus or newborn

## Protamine sulfate

### Section

#### Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule

### Indications

Haemorrhagic disorder due to other specified circulating anticoagulants

## Rivaroxaban

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

## Tranexamic acid

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

### Indications

Haemorrhage, not elsewhere classified

## Warfarin

### Section

Medicines affecting coagulation

Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt);  
0.5 mg (sodium salt)

### Indications

Other specified diseases of arteries or arterioles

Cerebral ischaemic stroke due to embolic occlusion

Venous thromboembolism

Atrial fibrillation